Lentinan Protocol — Complete Dosing & Administration Guide

Dosing

How muchdo I take?

Intravenous: Delivered straight into a vein through a drip (IV), done by a clinician.

Bioavailability Complete (about 100%) — delivered straight into the bloodstream.

Starting Dose

1 mg per dose

Frequency

Twice weekly

Duration

Continued alongside chemotherapy cycles

Established clinical regimen in Japan (approved 1985 as a biological response modifier for gastric cancer): 1 mg IV twice weekly combined with chemotherapy such as tegafur or 5-FU [1][6].

Standard Dose

2 mg per dose

Once weekly (some protocols every 2-3 weeks)

Alternative approved IV schedule: 2 mg once weekly; more recent protocols give 2 mg every 2-3 weeks. Used as an immunomodulatory adjunct to S-1/tegafur-based chemotherapy in advanced/recurrent gastric cancer [1][6].

Timing

Best time to take

Lentinan is administered intravenously in a clinical setting. Timing is determined by your healthcare provider based on the treatment protocol and your medical needs.

With food?

IV administration of Lentinan is not dependent on meal timing. Your healthcare team will provide specific instructions regarding food and fluid intake around treatment sessions.

If stacking

Lentinan should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

Adjusting Your Dose

Increase if

+Initial doses are well-tolerated and oncologist recommends escalation

+Immune response markers indicate room for further activation

+Higher doses are part of the specific clinical protocol being followed

Decrease if

-You experience infusion reactions such as fever, chills, or chest tightness

-Blood counts show granulocytopenia or other concerning changes

-Liver enzymes become elevated during treatment

-Your oncologist determines a lower dose is appropriate based on clinical response

Signs of right dose

✓Noticeable improvement in target symptoms

✓Good tolerance with minimal side effects

✓Consistent positive response between doses

✓Improved lab markers or clinical assessments (if applicable)

Dosing Calculator

Calculate Your Exact Dose

Step 1: Peptide Weight

Find the weight printed on your peptide vial label

Look here!

The peptide weight is printed on the label

The weight is on the label

Select Weight

Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)

Administration

How do Iuse it?

Reconstitution

What you need

•Lentinan vial (lyophilized powder or solution)

•Bacteriostatic water or sterile sodium chloride for reconstitution

•Alcohol swabs for cleaning vial tops and injection sites

•Appropriately sized syringes with fine-gauge needles (27-30 gauge)

•Sharps disposal container

Example

Add the recommended volume of bacteriostatic water to the Lentinan vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.

Your dose of Lentinan is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.

Injection

Route

Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training

Best sites

•Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection

•Front of thighs—middle to upper portion of the outer leg

•Back of upper arm—outer area (may need assistance from another person)

Technique

1.Wash your hands thoroughly with soap and water before handling supplies

2.Clean the injection site with an alcohol swab and let it air dry completely

3.Pinch a fold of skin at the chosen injection site

4.Insert the needle at a 45-90 degree angle (depending on needle length and body composition)

5.Inject the medication slowly and steadily over 5-10 seconds

6.Release the skin fold and remove the needle, applying gentle pressure with a clean swab

7.Rotate injection sites to prevent tissue irritation or lipodystrophy

8.Dispose of the needle safely in a sharps container—never recap or reuse needles

Storage

Before reconstitution

Store Lentinan in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.

After reconstitution

Once reconstituted, Lentinan should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.

Signs of degradation

Solution appears cloudy, discolored, or contains visible particles (should be clear)

Product has been exposed to temperatures outside the recommended storage range

Product has been frozen (unless specifically designed for freeze-thaw stability)

Expiration date has passed or reconstituted solution has exceeded its use-by date

Unusual odor, color change, or visible contamination

Sample Daily Schedule

As prescribed (once weekly)

As prescribed by your healthcare provider injection

Site: Intravenous infusion—rotate sites if applicable

Maintain a consistent schedule for optimal results with Lentinan. Set reminders if needed. If you miss a dose, follow your healthcare provider's instructions—do not double up on doses to compensate.

Safety

Is itsafe?

Safety Profile

Lentinan is a beta-1,3-glucan polysaccharide (not a true peptide) extracted from shiitake mushroom with a 40-year safety record in Japanese and Asian oncology practice. Parenteral lentinan shows excellent tolerability as an immune adjuvant with minimal systemic toxicity—hepatotoxicity and nephrotoxicity are essentially absent in clinical use. Fever and localized reactions at injection sites (5-15% of patients) are the documented side effects. The compound works through pattern recognition receptors (Dectin-1, TLR-2) to enhance NK cell and macrophage function without inducing autoimmunity.

Lentinan safety is established through decades of post-market surveillance in Japan where it is approved as an immune-modulating agent combined with chemotherapy in cancer treatment. Multiple randomized controlled trials in Anticancer Drugs and Journal of Interferon & Cytokine Research document safety and tolerability in immunocompromised and healthy populations. FDA has not approved lentinan in the US, but extensive clinical experience in Asia supports its use as an immunological adjuvant with favorable safety-to-efficacy ratio.

Common Side Effects

Experienced by some users

Fever and chills

Mild fever and chills may occur during or shortly after IV infusion as part of the immune activation response. This is the most common side effect and reflects lentinan's biological activity.

Management: Usually self-resolving within 24 hours. Slow the infusion rate if symptoms occur during administration. Antipyretics may be used for comfort.

Infusion site discomfort

Local discomfort, warmth, or mild pain at the IV infusion site is relatively common and typically resolves after the infusion is complete.

Management: Ensure proper IV line placement. Apply warm compress after infusion if needed. Report persistent pain or swelling to healthcare provider.

Transient fatigue

Mild tiredness or lethargy may occur in the hours or day following infusion, particularly during the first few treatments as the immune system responds to lentinan.

Management: Rest as needed. Fatigue typically diminishes with subsequent treatments. Schedule infusions when rest is possible afterward.

Nausea

Mild nausea may occur during or after infusion. Often difficult to distinguish from chemotherapy-related nausea in cancer patients receiving combination therapy.

Management: Anti-emetics may be used as needed. Taking light meals before infusion may help. Report persistent nausea to your healthcare provider.

Less Common

•Chest tightness or back pain

•Granulocytopenia

These typically resolve with continued use or dose adjustment.

Stop and Seek Help If

×Severe or worsening side effects that don't improve with dose adjustment or supportive care

×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing

×Your healthcare provider recommends discontinuation based on your clinical response

×Development of any new medical condition that may be contraindicated with Lentinan

×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)

×Abnormal lab results or clinical markers that suggest adverse effects

Lentinan should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

Interactions

With other peptides

✓Both enhance immune function through different mechanisms. Combination may provide synergistic antitumor immunity enhancement. Used together in some Asian oncology protocols.

✓Complementary mechanisms — Imunofan provides antioxidant protection and immune modulation while lentinan activates innate immunity through β-glucan receptor pathways. May reduce chemotherapy toxicity when used alongside lentinan-chemotherapy regimens.

✓No known interactions. BPC-157 focuses on tissue healing while lentinan targets immune activation. Could potentially support recovery from treatment side effects.

With medications

✓Chemotherapy drugs (cisplatin, tegafur, 5-FU) - Lentinan is specifically designed for use alongside chemotherapy. Clinical trials demonstrate enhanced efficacy and improved patient quality of life when combined. This is the intended clinical use.

!Immunosuppressants (cyclosporine, tacrolimus) - Lentinan's potent immune-activating effects may counteract the intended immunosuppression. Avoid concurrent use unless specifically directed by a physician.

✓Antiretroviral therapy (HIV) - Clinical trials have combined lentinan with didanosine (ddI) for HIV treatment. The combination was generally tolerated but rapid IV infusion caused adverse effects. Use under close medical supervision.

✓Anticoagulants - Some β-glucans may have mild anticoagulant properties. While not specifically documented for lentinan, caution is advised with concurrent blood-thinning medications.

With supplements

✓Vitamin D - Vitamin D supports immune function and may complement lentinan's immunomodulatory effects. Safe to combine.

✓Other mushroom extracts (reishi, turkey tail) - Multiple mushroom-derived β-glucans may provide additive immune effects. While generally safe, excessive immune stimulation is theoretically possible. Use under healthcare provider guidance.

✓Selenium - Selenium supports antioxidant defense systems and may complement lentinan's anticancer effects. No known negative interactions.

✓Green tea extract (EGCG) - Both have demonstrated anticancer properties through different mechanisms. May provide complementary benefits. No known negative interactions.

Want the Full Picture?

View the complete Lentinan research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.